Document Detail

Thrombotic and Hemorrhagic Complications of Stenting Coronary Arteries: Incidence, Management, and Prevention.
MedLine Citation:
PMID:  10608007     Owner:  NLM     Status:  Publisher    
Stents are intravascular prostheses which provide endoluminal scaffolding, effectively reducing elastic recoil and sealing local dissections. Stents have become the treatment of choice for acute vessel closure following percutaneous coronary intervention. In addition, by providing a large, smooth lumen, stenting increases procedural success and decreases late restenosis compared with conventional balloon angioplasty. All stents evaluated clinically are constructed of non-corrosive metallic alloys which are inherently thrombogenic.The incidence of stent thrombosis ranges from 0.4-18%. While acute thrombosis is uncommon, subacute thrombosis may occur from 5 to 21 days (mean 7 days) after placement. Predictors of stent thrombosis include stenting for bailout indication, angiographically visible thrombus after implantation, stenting of smaller vessels, presence of residual dissection after stenting, poor distal runoff, incomplete stent expansion and stenting in the setting of acute myocardial infarction. Stent thrombosis is associated with high incidence of Q-wave myocardial infarction (70-90%) and mortality (7-20%), and is best treated with emergency catheterization and balloon angioplasty.To prevent stent thrombosis, aggressive procedural and postprocedural pharmacological regimens employing antiplatelet agents (aspirin, dipyridamole and dextran) and anticoagulation (heparin followed by warfarin) have been used. While these regimens have reduced the incidence of stent thrombosis to <5%, they are associated with a high incidence of vascular and hemorrhagic complications, increased length of hospitalization and total cost. To decrease the incidence of stent thrombosis and obviate the need for anticoagulation, strategies such as intravascular ultrasound guided "optimal stenting" and addition of the antiplatelet agent ticlopidine, are being evaluated. In the future coating of stents with agents such as heparin, may further reduce the risk of thrombosis and the requirement for long-term anticoagulation.
Carrozza; Baim
Related Documents :
7754937 - Effect of intracoronary ultrasound imaging on clinical decision making.
17712217 - Usefulness of the safecut dual wire ptca catheter for the treatment of calcified lesions.
17452147 - The cobalt chromium stent with antiproliferative for restenosis ii (costar ii) trial st...
20339967 - Elective coronary stent patients: preinterventional functional status and clinical-inst...
6344767 - Right ventricular infarction.
11442937 - Transesophageal color doppler echocardiographic diagnosis of cardiac rupture following ...
Publication Detail:
Journal Detail:
Title:  Journal of thrombosis and thrombolysis     Volume:  1     ISSN:  1573-742X     ISO Abbreviation:  J. Thromb. Thrombolysis     Publication Date:  1995  
Date Detail:
Created Date:  1999-12-22     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9502018     Medline TA:  J Thromb Thrombolysis     Country:  -    
Other Details:
Languages:  ENG     Pagination:  289-297     Citation Subset:  -    
Charles A. Dana Research Institute and Harvard-Thorndike Laboratory, Cardiovascular Division, Beth Israel Hospital, Boston, Massachusetts.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Monitoring Anticoagulation During Percutaneous Coronary Interventions.
Next Document:  Vascular Applications of Human Gene Therapy.